Company: RPID
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001380106-25-000174
Chunk: 260

Company: RAPID MICRO BIOSYSTEMS, INC.
Filing Date: 2025-08-12
Form: 10-Q
Item: Part II, Item 1A
Chunk 260
---
•the continued growth of the pharmaceutical and biopharmaceutical industry, in particular biologics and cell and gene therapies;

•our ability to execute on our business strategy, including continuing to expand in the market for cell and gene therapies;

•the rate of adoption of our platform and solutions by drug manufacturers;

•prices we charge for our systems and consumables;

•the relative reliability and robustness of our platform as a whole and the components of our platform;

•our ability to develop new products for existing customers and to expand our capabilities within the MQC testing workflow;

•our ability to expand the use of our platform with existing customers;

•other competitive automated MQC testing platforms; and

•the impact of our investments in product innovation and commercial growth.

We cannot assure our stockholders that we will be successful in addressing each of these criteria or other criteria that might affect the market acceptance of our products. If we are unsuccessful in achieving and maintaining commercial market acceptance of our Growth Direct platform, our business, financial condition, results of operations and prospects could be adversely affected.

Our operating results have fluctuated significantly in the past and will fluctuate significantly in the future, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations.

Our quarterly and annual operating results have fluctuated significantly in the past and may fluctuate significantly in the future, which makes it difficult for us to predict our future operating results. For example, we have experienced positive trends in our gross margins, improving from (3)% to 4% for the three months ended June 30, 2024 and June 30, 2025, respectively, and improving from (14)%  to 5% for the six months ended June 30, 2024 and June 30, 2025, 

47

Table of Contents

respectively. Expansion in gross margins in future periods may not be linear and may be subject to variability from period to period. Additionally, revenue growth and operating expenses may also be subject to variability from period to period. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to:

•our customers’ tendency to purchase our Growth Direct system, including multiple systems, in a single transaction, resulting in significant variations in sales of our systems over time;

•the level of demand for our platform and solutions, which may vary significantly;

•the length of time of the sales cycle for purchases of our systems;

•seasonality in